Wednesday, January 18, 2006

Lilly Licenses Xencor's ImmunoFilter(TM) Technology; Proprietary Tool to Assess Potential Protein Immunogenicity for more than 95% of U.S. Population

1/18/2006 8:00:00 AM EST
Xencor, Inc., a biotherapeutics company developing protein and antibody therapeutics, today announced that it has granted Eli Lilly and Company a non-exclusive license to use Xencor's ImmunoFilter technology to evaluate the potential immunogenicity of its therapeutic proteins. ImmunoFilter is a new predictive tool designed to enable Xencor and its partners to identify risk of future immunogenicity in antibody and other protein therapeutic candidates. Immunogenicity may reduce the therapeutic efficacy of a protein drug and may trigger potentially severe adverse events.

Xencor's ImmunoFilter tools were developed based on a proprietary immunochemical data set of peptide agretope binding to class II major histocompatibility complex ("MHC") proteins, a key determinant of recognition of antigens by the immune system. Capable of assessing potential immunogenicity for more than 95% of the U.S. population and based on empirical binding data, ImmunoFilter technology is the first predictive method to use direct experimental measurements to catalog the breadth of MHC-peptide interactions.
"We are excited to expand our relationship with Lilly and to enable our colleagues to use our proprietary data and software to assess the potential immunogenicity of their drug candidates across a large portion of the U.S. population," said Bassil Dahiyat, Ph.D., President and CEO of Xencor. "Using ImmunoFilter technology, we and our partners are able to identify potential 'hotspots' on protein drug candidates very early in the development process, and to potentially minimize the future risk of immunogenicity using protein engineering and other technologies. We believe the high-quality data that the ImmunoFilter approach is based on sets it apart from other approaches to assess immunogenicity."
Under the terms of the agreement, Xencor granted to Lilly a multi-year license to Xencor's ImmunoFilter data and software and may experimentally scan specific proteins of interest on Lilly's behalf. Specific financial terms were not disclosed.

About ImmunoFilter(TM) Technology
ImmunoFilter technology focuses on MHC binding of protein-derived peptides to predict the presence of class II major histocompatibility complex ("MHC") agretopes in a protein sequence. Consisting of a database of proprietary immunochemical measurements and software, ImmunoFilter tools rapidly scan therapeutic protein candidates of interest. The ImmunoFilter database comprehensively addresses the high sequence diversity of MHC proteins among patient populations, and was generated from experimental measurements of peptide binding to a large set of class II MHC proteins. This provides nearly complete coverage of the MHC diversity present in the U.S. population. Xencor's ImmunoFilter technology was developed with funding from an Advanced Technology Program grant from the National Institute of Standards and Technology.

About Xencor
Xencor, Inc., engineers superior biotherapeutics using its proprietary Protein Design Automation(R) technology platform. The company is internally advancing both XPro(TM) protein therapeutic candidates and XmAb(TM) antibody drug candidates optimized for activity against biologically validated targets. Xencor's product development is led by a protein therapeutic drug candidate, XPro1595, for the treatment of arthritis and other rheumatic disorders and antibody candidates for the treatment of cancer. With multiple partners, such as industry leaders Genentech, Roche, Centocor and MedImmune, Xencor is applying its suite of XmAb antibody Fc domains to improve antibody drug candidates for traits such as potency and sustained half-life. Xencor also develops therapeutic protein variants in collaboration with major pharmaceutical partners. For more information, please visit www.xencor.com.

www.genengnews.com

Scotiabank Selects Fair Isaac's Debt Manager Web Solution

Published: January 18, 2006
The solution combines streamlined workflow processes with a comprehensive view of each customer and their related accounts.
Fair Isaac Corp., a provider of analytics and decision management technology, recently announced that Scotiabank is uses Fair Isaac's Debt Manager Web solution to support its international collections initiatives.
Debt Manager Web is capable of managing millions of accounts with users operating at a single site or across multiple locations, and supports Scotiabank's customer-centric approach for managing consumer debt. The integrated collections and recovery software solution combines streamlined workflow processes with a comprehensive view of each customer and their related accounts.

The application's sophisticated account segmentation and decisioning capabilities allow Scotiabank to execute the optimal collection strategy for the entire customer relationship across the bank, resulting in increased customer service and loyalty, and improved efficiency and productivity.
"This implementation represents a significant success for both Scotiabank and Fair Isaac," said Dale Williams, Vice President of Collections and Recovery Solutions at Fair Isaac. "Scotiabank came to us with a vision to create a better, holistic collections infrastructure, and Debt Manager is the ideal solution to deliver this 'big picture' approach. We look forward to helping Scotiabank meet the needs of their customers and achieve business success in the many different markets they serve."

http://www.b-eye-network.com/

Pioneer in solid-fuel rock technology dies

THE ASSOCIATED PRESS
LOS ANGELES -- Col. Edward N. Hall, who as director of the Minuteman intercontinental ballistic missile program helped develop the country's solid-fuel rocket technology, putting the U.S. decades ahead of other superpowers, has died. He was 91.
Hall died Sunday at Torrance Memorial Medical Center, said his daughter, Sheila Hall. The cause of death was not immediately known.

Hall's immense knowledge of rocket propellants helped the Air Force create its first solid-fuel ICBM in the late 1950s. The switch from liquid fuel to solid made missiles smaller, easier to deploy and less expensive.
The Minuteman became the country's premier missile defense system. It took countries such as the former Soviet Union and China decades to create similar programs.
"It's on a short list of military marvels of the 20th century ... right up there with the Manhattan Project," John Pike, director of the military information Web site, globalsecurity.org, said of the accomplishments of Hall and those he worked with.
Hall was born in New York City in 1914 and received a bachelor's degree in engineering from City College of New York in 1935. He later earned a master's in aeronautical engineering from California Institute of Technology.

After enlisting in the Army Air Corps during World War II, he was deployed to England where he repaired U.S. aircraft. Near the war's end he was assigned to acquire intelligence on Germany's rocket propulsion equipment and studied parts recovered from V-2 rockets.
After the war, Hall was assigned to Wright-Patterson Air Force Base in Dayton, Ohio, where he worked on liquid-fueled rocket engines. While there, he built a rocket that had a thrust of 135,000 pounds - more than double the power exerted by the German V-2.
Hall left the Air Force in 1959 and spent 14 years as an engineer at United Aircraft Corp. In retirement, he was a consultant for engineering and aerospace companies.

seattlepi.nwsource.com

ARAB LAB 2006: The international show for tomorrow's technology

The greatest annual tradeshow for the laboratory and instrumentation industry in the Middle East, ARAB LAB opens far-reaching comprehensive buying and sourcing opportunities in mainstream sectors namely Biotechnology, Automation, Instrumentation, Robotics, Laboratory, Technology and Diagnostics. ARAB LAB, to be held at Sheikh Maktoum and Sheikh Rashid Halls at Dubai International Exhibiton Centre, will also feature a multi-sector seminar session, which will bring to one common platform some of the most sought after speakers in the laboratory and instrumentation industry. This mega event is expected to show a phenomenal growth percentage over the previous edition. Last year, ARAB LAB witnessed more than 7,400 trade visitors and industry professionals from 75 countries. This year, the registration has gone much higher and is expected to break its previous records. The dynamic growth achieved by the event has resulted in new levels of quality and recognition. ARAB LAB serves the Arab World and the MENA region and it presents products and services to professional visitors and buyers from these places. The visitors for the event include global buyers and users of laboratory equipment and instrumentation for sectors like health, industry, aquaculture, public services, environment and education. A unique event like ARAB LAB becomes even more important as major investment opportunities are opened up in the Arab World as well as the MENA Region. Thanks to the governments in these regions who are allocating massive budgets for projects in the fields of analysis, research and development. The areas like infrastructure, environment and biotechnology are also creating huge opportunities for the Laboratory and Instrumentation industry. At the same time, ARAB LAB offers a never before opportunity for the exhibitors at the show as they enjoy direct access to new business contacts, developing new markets, networking competitive activity, supporting dealer network, accessing latest public and private tenders, selling more products and services, establishing new agents, sourcing new suppliers and services, and presenting technical seminars. Organised by the Domus Group - one of the most experienced and established exhibition organizers in the Middle East, ARAB LAB is a truly international show for tomorrow's technology.